J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.

On an earnings call dominated by discussion about the impact of biosimilar competition to its top-seller Remicade (infliximab), Johnson & Johnson pointed to a growing oncology business and an abundant late-stage pipeline on Oct. 18, saying it will file 10 new molecular entities for approval during 2015-2019 that have blockbuster sales potential.

In cancer, Worldwide Chairman-Pharmaceuticals Joaquin Duato cited continued sales growth for Imbruvica (ibrutinib) and a promising launch for Darzalex (daratumumab)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business